# Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/istituto-nazionale-per-le-malattie-infettive-lazzaro-spallanzani/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 74.5 |
| Citations | 778,403 |
| City | Rome |
| Country | IT |
| Description | Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani is a research organisation in Rome, IT. OpenAlex records 5,862 works and 778,403 citations for it. 1,293 researchers list it as their most recent affiliation. |
| Homepage | http://www.inmi.it/ |
| OpenAlex ID | https://openalex.org/I4210091493 |
| Researchers | 1,293 |
| ROR ID | https://ror.org/00kv87w35 |
| Type | healthcare |
| Works | 5,862 |

## University papers

- [Updated research nosology for HIV-associated neurocognitive disorders](https://scholariq.org/papers/updated-research-nosology-for-hiv-associated-neurocognitive-disorders/)
- [Towards tuberculosis elimination: an action framework for low-incidence countries](https://scholariq.org/papers/towards-tuberculosis-elimination-an-action-framework-for-low-incidence-countries/)
- [The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement](https://scholariq.org/papers/the-risk-of-tuberculosis-related-to-tumour-necrosis-factor-antagonist-therapies/)
- [Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials](https://scholariq.org/papers/dolutegravir-plus-lamivudine-versus-dolutegravir-plus-tenofovir-disoproxil/)
- [ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population](https://scholariq.org/papers/ace2-gene-variants-may-underlie-interindividual-variability-and-susceptibility/)
- [No metagenomic evidence of tumorigenic viruses in cancers from a selected cohort of immunosuppressed subjects](https://scholariq.org/papers/no-metagenomic-evidence-of-tumorigenic-viruses-in-cancers-from-a-selected-cohort/)
- [MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network](https://scholariq.org/papers/mdr-xdr-tb-management-of-patients-and-contacts-challenges-facing-the-new-decade/)
- [Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January–April 2020](https://scholariq.org/papers/worldwide-effects-of-coronavirus-disease-pandemic-on-tuberculosis-services/)
- [JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality](https://scholariq.org/papers/jak-inhibition-reduces-sars-cov-2-liver-infectivity-and-modulates-inflammatory/)
- [Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study](https://scholariq.org/papers/association-of-toll-like-receptor-7-variants-with-life-threatening-covid-19/)
- [Assessment, Diagnosis, and Treatment of HIV-Associated Neurocognitive Disorder: A Consensus Report of the Mind Exchange Program](https://scholariq.org/papers/assessment-diagnosis-and-treatment-of-hiv-associated-neurocognitive-disorder-a/)
- [Epidemic and pandemic viral infections: impact on tuberculosis and the lung](https://scholariq.org/papers/epidemic-and-pandemic-viral-infections-impact-on-tuberculosis-and-the-lung/)

## University top topics

Showing 8 of 25.

- [HIV Research and Treatment](https://scholariq.org/topics/hiv-research-and-treatment/)
- [HIV/AIDS drug development and treatment](https://scholariq.org/topics/hiv-aids-drug-development-and-treatment/)
- [HIV/AIDS Research and Interventions](https://scholariq.org/topics/hiv-aids-research-and-interventions/)
- [Tuberculosis Research and Epidemiology](https://scholariq.org/topics/tuberculosis-research-and-epidemiology/)
- [Hepatitis C virus research](https://scholariq.org/topics/hepatitis-c-virus-research/)
- [HIV-related health complications and treatments](https://scholariq.org/topics/hiv-related-health-complications-and-treatments/)
- [SARS-CoV-2 and COVID-19 Research](https://scholariq.org/topics/sars-cov-2-and-covid-19-research/)
- [COVID-19 Clinical Research Studies](https://scholariq.org/topics/covid-19-clinical-research-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.